The genomic risk stratification testing market is projected to grow from USD 4.2 billion in 2026 to USD 12.1 billion by 2036, at a CAGR of 11.2%. NGS-based tests will dominate with a 42.0% market share, while oncology risk profiling will lead the application segment with a 46.0% share.